Literature DB >> 1548358

Renal handling of phosphate can predict height velocity during growth hormone therapy for short children.

S Nishiyama1, M Ikuta, T Nakamura, S Tomoeda, I Matsuda.   

Abstract

Renal tubular reabsorption of phosphate in response to GH administration was studied in 28 short Japanese children, aged 5-11 yr (height SD score, less than -2.0 SD). Three groups included a classical GH deficiency (group 1; n = 12), a partial GH deficiency (group 2; n = 7), and children with non-GH deficiency (group 3; n = 9), depending on the peak response of serum GH in four provocative tests. Serum phosphorus, alkaline phosphatase, insulin-like growth factor-I (IGF-I), osteocalcin, and ratio of the maximum tubular reabsorption rate for phosphorus to the glomerular filtration rate (Tmp/GFR) were all significantly lower in group 1 compared with findings in groups 2 and 3 (P less than 0.05, P less than 0.01, and P less than 0.001). After the administration of GH (0.1 U/kg.day) for 4 consecutive days, increments in serum phosphorus and Tmp/GFR were significantly higher in group 1 than in group 2 (P less than 0.01 and P less than 0.01) or group 3 (P less than 0.01 and P less than 0.01), whereas the increment in IGF-I was similar in all 3 groups, and the levels of serum alkaline phosphatase and osteocalcin remained unchanged in all 3 groups. The calculated ratio of the increment in Tmp/GFR to the increment in IGF-I (delta Tmp/GFR/delta IGF-I) was highest in group 1, intermediate in group 2, and lowest in group 3 (P less than 0.001). One year after the GH treatment (0.5 U/kg.week), height velocity was 7.9 +/- 2.2 cm/yr in group 1 and 5.9 +/- 1.2 cm/yr in group 2; no child in group 3 was treated. When the above calculated parameters, delta Tmp/GFR/delta IGF-I and increment in height velocity (difference between pre- and posttherapy values), were taken into account, there was a significant positive correlation (n = 19; r = 0.78; P less than 0.001). This parameter can be used for purposes of predicting the outcome after 1 yr of GH therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548358     DOI: 10.1210/jcem.74.4.1548358

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Growth hormone secretion in poorly growing children with renal hypophosphataemic rickets.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; G Perri
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

2.  Association between decreased klotho blood levels and organic growth hormone deficiency in children with growth impairment.

Authors:  Ido Wolf; Shiri Shahmoon; Michal Ben Ami; Yael Levy-Shraga; Kineret Mazor-Aronovitch; Orit Pinhas-Hamiel; Yonatan Yeshayahu; Rina Hemi; Hannah Kanety; Tami Rubinek; Dalit Modan-Moses
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.